Lamotrigine 25/100/150/200 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Seizure Disorders (Epilepsy)

• Levetiracetam
• Topiramate
• Levetiracetam 250/500/750/1000 mg tabs
• Topiramate 25/50/100 mg tabs

What Lamotrigine 25/100/150/200 mg tabs is approved for (FDA label)

Lamotrigine is indicated for: Epilepsy — adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. (1.1) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended.

Source: Read the full FDA label on DailyMed. Label effective date: September 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Lamotrigine 25/100/150/200 mg tabs (FDA label)

WARNING: SERIOUS SKIN RASHES Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking lamotrigine as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate. In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by lamotrigine include (1) coadministration of lamotrigine with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine, or (3) exceeding the recommended dose escalation for lamotrigine, or (4) the presence of the HLA-B*1502 allele. However, cases have occurred in the absence of these factors. Nearly all cases of life-threatening rashes caused by lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.

Source: FDA prescribing information (DailyMed). Set ID: 20e156df-a2b6-4710-b526-0419cd17dd33. SPL document ID: cc4537ab-8839-4f4e-a232-0cf7a52d2f39. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lamotrigine 25/100/150/200 mg tabs (FDA label)

• Tablets: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg (3.1 , 16) • Tablets for Oral Suspension: 5 mg and 25 mg. (3.2 , 16) 3.1 Tablets 25 mg, white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "79" and other side is plain. 50 mg, white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "90" and other side is plain. 100 mg, white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "80"and other side is plain. 150 mg, white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "81" and other side is plain. 200 mg, white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "82" and other side is plain. 250 mg, white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "91"and other side is plain. 3.2 Tablets for Oral Suspension, USP 5 mg, white to off-white, round, flat- faced, radial-edged tablets with bisect on one side and plain on other side; one side of the bisect is debossed with "Z" and other side is debossed with "13". 25 mg, white to off-white, round, flat- faced, radial-edged tablets debossed with logo of "Z" and "12" on one side and plain on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 20e156df-a2b6-4710-b526-0419cd17dd33. SPL document ID: cc4537ab-8839-4f4e-a232-0cf7a52d2f39. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lamotrigine 25/100/150/200 mg tabs (FDA label)

The following serious adverse reactions are described in more detail in the Warnings and Precautions section of the labeling: • Serious Skin Rashes [see Warnings and Precautions (5.1) ] • Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5.2) ] • Multiorgan Hypersensitivity Reactions and Organ Failure [see Warnings and Precautions (5.3) ] • Cardiac Rhythm and Conduction Abnormalities [see Warnings and Precautions (5.4) ] • Blood Dyscrasias [see Warnings and Precautions (5.5) ] • Suicidal Behavior and Ideation [see Warnings and Precautions (5.6) ] • Aseptic Meningitis [see Warnings and Precautions (5.7) ] • Withdrawal Seizures [see Warnings and Precautions (5.10) ] • Status Epilepticus [see Warnings and Precautions (5.11) ] • Epilepsy: Most common adverse reactions (incidence ≥10%) in adults were dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, pharyngitis, and rash.

Source: FDA prescribing information (DailyMed). Set ID: 20e156df-a2b6-4710-b526-0419cd17dd33. SPL document ID: cc4537ab-8839-4f4e-a232-0cf7a52d2f39. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lamotrigine 25/100/150/200 mg tabs (FDA label)

Lamotrigine is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see Boxed Warning , Warnings and Precautions (5.1) , (5.3) ]. Hypersensitivity to the drug or its ingredients. (Boxed Warning , 4)

Source: FDA prescribing information (DailyMed). Set ID: 20e156df-a2b6-4710-b526-0419cd17dd33. SPL document ID: cc4537ab-8839-4f4e-a232-0cf7a52d2f39. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lamotrigine 25/100/150/200 mg tabs (FDA label)

• Life-threatening serious rash and/or rash-related death: Discontinue at the first sign of rash, unless the rash is clearly not drug related. (Boxed Warning , 5.1) • Hemophagocytic lymphohistiocytosis: Consider this diagnosis and evaluate patients immediately if they develop signs or symptoms of systemic inflammation. Discontinue lamotrigine if an alternative etiology is not established. (5.2) • Fatal or life-threatening hypersensitivity reaction: Multiorgan hypersensitivity reactions, also known as drug reaction with eosinophilia and systemic symptoms, may be fatal or life threatening. Early signs may include rash, fever, and lymphadenopathy. These reactions may be associated with other organ involvement, such as hepatitis, hepatic failure, blood dyscrasias, or acute multiorgan failure. Lamotrigine should be discontinued if alternate etiology for this reaction is not found. (5.3) • Cardiac rhythm and conduction abnormalities: Based on in vitro findings, lamotrigine could cause serious arrhythmias and/or death in patients with certain underlying cardiac disorders or arrhythmias.

Source: FDA prescribing information (DailyMed). Set ID: 20e156df-a2b6-4710-b526-0419cd17dd33. SPL document ID: cc4537ab-8839-4f4e-a232-0cf7a52d2f39. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lamotrigine 25/100/150/200 mg tabs (FDA label)

Significant drug interactions with lamotrigine are summarized in this section. Uridine 5´-diphospho-glucuronyl transferases (UGT) have been identified as the enzymes responsible for metabolism of lamotrigine. Drugs that induce or inhibit glucuronidation may, therefore, affect the apparent clearance of lamotrigine. Strong or moderate inducers of the cytochrome P450 3A4 (CYP3A4) enzyme, which are also known to induce UGT, may also enhance the metabolism of lamotrigine.

Source: FDA prescribing information (DailyMed). Set ID: 20e156df-a2b6-4710-b526-0419cd17dd33. SPL document ID: cc4537ab-8839-4f4e-a232-0cf7a52d2f39. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.